Which has stronger earnings & valuation, ODTX or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Odyssey Therapeutics N/A N/A N/A -$6.77 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is ODTX or DYN more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Dyne Therapeutics N/A -64.30% -50.33%

Does the media prefer ODTX or DYN?

In the previous week, Dyne Therapeutics had 32 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 34 mentions for Dyne Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Dyne Therapeutics' score of 0.44 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ODTX or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Odyssey Therapeutics N/A N/A N/A -$6.77 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is ODTX or EWTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Edgewise Therapeutics N/A -39.01% -36.96%

Does the media refer more to ODTX or EWTX?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Edgewise Therapeutics' score of 1.21 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CELC or ODTX?

Celcuity is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Odyssey Therapeutics N/A N/A N/A -$6.77 N/A

Is CELC or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Odyssey Therapeutics N/A N/A N/A

Does the media refer more to CELC or ODTX?

In the previous week, Celcuity had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Celcuity's score of 1.24 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ODTX or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Odyssey Therapeutics N/A N/A N/A -$6.77 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is ODTX or ELVN more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Enliven Therapeutics N/A -18.55% -18.09%

Does the media favor ODTX or ELVN?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for Odyssey Therapeutics. Enliven Therapeutics' average media sentiment score of 1.51 beat Odyssey Therapeutics' score of 1.45 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is ODTX or RLAY more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer ODTX or RLAY?

In the previous week, Relay Therapeutics had 13 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 15 mentions for Relay Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Relay Therapeutics' score of 0.93 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Odyssey Therapeutics (ODTX) Competitors

$23.64 -0.87 (-3.55%)

As of 09/10/2026 04:00 PM Eastern

Compare

ODTX vs. DYN, EWTX, CELC, ELVN, and RLAY

Should you buy Odyssey Therapeutics stock or one of its competitors? Odyssey Therapeutics's main competitors and comparable companies include Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Celcuity (CELC), Enliven Therapeutics (ELVN), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Odyssey Therapeutics compare to Dyne Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Odyssey Therapeutics' return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 32 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 34 mentions for Dyne Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Dyne Therapeutics' score of 0.44 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Odyssey Therapeutics presently has a consensus target price of $35.75, indicating a potential upside of 51.23%. Dyne Therapeutics has a consensus target price of $32.17, indicating a potential upside of 74.63%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

Summary

Dyne Therapeutics beats Odyssey Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Edgewise Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Odyssey Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-39.01%	-36.96%

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Edgewise Therapeutics' score of 1.21 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics presently has a consensus price target of $35.75, suggesting a potential upside of 51.23%. Edgewise Therapeutics has a consensus price target of $50.33, suggesting a potential upside of 17.33%. Given Odyssey Therapeutics' higher probable upside, equities analysts clearly believe Odyssey Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Odyssey Therapeutics and Edgewise Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Odyssey Therapeutics' return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Odyssey Therapeutics	N/A	N/A	N/A

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Celcuity had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Celcuity and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Celcuity's score of 1.24 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Celcuity presently has a consensus price target of $154.55, indicating a potential upside of 80.78%. Odyssey Therapeutics has a consensus price target of $35.75, indicating a potential upside of 51.23%. Given Celcuity's stronger consensus rating and higher probable upside, equities analysts plainly believe Celcuity is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Celcuity beats Odyssey Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Enliven Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Odyssey Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Enliven Therapeutics	N/A	-18.55%	-18.09%

In the previous week, Enliven Therapeutics had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for Odyssey Therapeutics. Enliven Therapeutics' average media sentiment score of 1.51 beat Odyssey Therapeutics' score of 1.45 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Odyssey Therapeutics currently has a consensus target price of $35.75, suggesting a potential upside of 51.23%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 33.38%. Given Odyssey Therapeutics' higher probable upside, research analysts plainly believe Odyssey Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats Odyssey Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Relay Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Relay Therapeutics had 13 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 15 mentions for Relay Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.45 beat Relay Therapeutics' score of 0.93 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Relay Therapeutics	N/A	-42.27%	-38.67%

Odyssey Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Relay Therapeutics	$15.35M	269.68	-$276.48M	-$1.57	N/A

Odyssey Therapeutics currently has a consensus target price of $35.75, suggesting a potential upside of 51.23%. Relay Therapeutics has a consensus target price of $25.92, suggesting a potential upside of 37.20%. Given Odyssey Therapeutics' higher possible upside, equities analysts plainly believe Odyssey Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Odyssey Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Odyssey Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ODTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ODTX vs. The Competition

Export

Metric	Odyssey Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.18B	$3.89B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	-3.49	13.60	272.82	25.11
Price / Sales	N/A	1,333.40	620.94	90.53
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	N/A	15.38	10.43	6.18
Net Income	N/A	-$22.82M	$3.49B	$358.18M
7 Day Performance	-17.80%	-3.97%	-3.16%	-2.51%
1 Month Performance	16.17%	0.27%	0.02%	-2.73%
1 Year Performance	N/A	38.62%	17.34%	7.73%

Odyssey Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ODTX Odyssey Therapeutics	3.4262 of 5 stars	$23.64 -3.5%	$35.75 +51.2%	N/A	$1.18B	N/A	N/A	N/A	News Coverage Positive News
DYN Dyne Therapeutics	3.0879 of 5 stars	$25.07 -3.9%	$34.42 +37.3%	+38.7%	$4.68B	N/A	N/A	100	Trending News Analyst Forecast Insider Trade Options Volume
EWTX Edgewise Therapeutics	3.2561 of 5 stars	$42.76 -3.2%	$50.33 +17.7%	+192.4%	$4.64B	N/A	N/A	60	Positive News
CELC Celcuity	2.6024 of 5 stars	$88.44 -5.1%	$154.55 +74.7%	+52.9%	$4.33B	N/A	N/A	40	Positive News
ELVN Enliven Therapeutics	2.5439 of 5 stars	$57.86 -4.4%	$75.00 +29.6%	+192.6%	$4.24B	N/A	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ODTX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. DYN, EWTX, CELC, ELVN, and RLAY

How does Odyssey Therapeutics compare to Dyne Therapeutics?

Summary

How does Odyssey Therapeutics compare to Edgewise Therapeutics?

Summary

How does Odyssey Therapeutics compare to Celcuity?

Summary

How does Odyssey Therapeutics compare to Enliven Therapeutics?

Summary

How does Odyssey Therapeutics compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. DYN, EWTX, CELC, ELVN, and RLAY

How does Odyssey Therapeutics compare to Dyne Therapeutics?

Is ODTX or DYN more profitable?

Does the media prefer ODTX or DYN?

Which has stronger earnings & valuation, ODTX or DYN?

Do institutionals & insiders hold more shares of ODTX or DYN?

Do analysts rate ODTX or DYN?

Summary

How does Odyssey Therapeutics compare to Edgewise Therapeutics?

Which has stronger earnings & valuation, ODTX or EWTX?

Is ODTX or EWTX more profitable?

Does the media refer more to ODTX or EWTX?

Do analysts rate ODTX or EWTX?

Summary

How does Odyssey Therapeutics compare to Celcuity?

Is CELC or ODTX more profitable?

Do insiders & institutionals believe in CELC or ODTX?

Does the media refer more to CELC or ODTX?

Which has stronger earnings and valuation, CELC or ODTX?

Do analysts recommend CELC or ODTX?

Summary

How does Odyssey Therapeutics compare to Enliven Therapeutics?

Is ODTX or ELVN more profitable?

Does the media favor ODTX or ELVN?

Do analysts recommend ODTX or ELVN?

Which has better earnings and valuation, ODTX or ELVN?

Do institutionals & insiders have more ownership in ODTX or ELVN?

Summary

How does Odyssey Therapeutics compare to Relay Therapeutics?

Does the media prefer ODTX or RLAY?

Is ODTX or RLAY more profitable?

Which has preferable valuation & earnings, ODTX or RLAY?

Do analysts recommend ODTX or RLAY?

Do insiders and institutionals have more ownership in ODTX or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools